TALEN

TALEN1-myh7l

ID

ZDB-TALEN-231010-1

Name

TALEN1-myh7l

Previous Names

None

Target

myh7l (1)

Target Sequence 1

5' - TCAAGGGTCTGTGCCATC - 3'

Target Sequence 2

5' - TTGGTGACCCACTCATTT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
xu093	myh7l

Expression

Gene expression in Wild Types + TALEN1-myh7l

No data available

Phenotype

Phenotype resulting from TALEN1-myh7l

No data available

Phenotype of all Fish created by or utilizing TALEN1-myh7l

Phenotype	Fish	Conditions	Figures
heart adenylate cyclase-activating adrenergic receptor signaling pathway decreased process quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: carvedilol	Figure 3 from Bu et al., 2021
atrium sarcomere ab-f59 labeling spatial pattern, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 , Figure 4 from Bu et al., 2021
heart contraction decreased process quality, ameliorated	myh7l^xu093/xu093	chemical treatment by environment: PD 0325901	Figure 3 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: sildenafil	Figure 3 from Bu et al., 2021
cardiac ventricle sarcomere ab1-tnnt labeling spatial pattern, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 from Bu et al., 2021
atrium sarcomere ab1-tnnt labeling spatial pattern, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 from Bu et al., 2021
pericardium edematous, ameliorated	myh7l^xu093/xu093	chemical treatment by environment: PD 0325901	Figure 3 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 , Figure 4 from Bu et al., 2021
pericardium edematous, abnormal	myh7l^xu093/xu093	chemical treatment by environment: vorinostat	Figure 3 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: cyclosporin A	Figure 3 from Bu et al., 2021
heart contraction decreased process quality, ameliorated	myh7l^xu093/xu093	chemical treatment by environment: sirolimus	Figure 3 from Bu et al., 2021
whole organism viability, abnormal	myh7l^xu093/xu093	standard conditions	Figure 4 from Bu et al., 2021
heart increased size, abnormal	myh7l^xu093/xu093	standard conditions	Figure 4 from Bu et al., 2021
MAPK cascade decreased process quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: PD 0325901	Figure 3 from Bu et al., 2021
pericardium edematous, abnormal	myh7l^xu093/xu093	chemical treatment by environment: sildenafil	Figure 3 from Bu et al., 2021
atrium increased size, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 from Bu et al., 2021
heart contraction decreased process quality, ameliorated	myh7l^xu093/xu093	chemical treatment by environment: carvedilol	Figure 3 from Bu et al., 2021
cardiac ventricle sarcomere ab-f59 labeling spatial pattern, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: vorinostat	Figure 3 from Bu et al., 2021
whole organism myh7l expression decreased amount, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 from Bu et al., 2021
pericardium edematous, ameliorated	myh7l^xu093/xu093	chemical treatment by environment: carvedilol	Figure 3 from Bu et al., 2021
heart TOR complex decreased object quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: sirolimus	Figure 3 from Bu et al., 2021
cardiac muscle cell nucleus increased size, abnormal	myh7l^xu093/xu093	standard conditions	Figure 5 from Bu et al., 2021
regulation of autophagy decreased process quality, abnormal	myh7l^xu093/xu093	chemical treatment by environment: sirolimus	Figure 3 from Bu et al., 2021
cardiac ventricle cardiac muscle cell shape, abnormal	myh7l^xu093/xu093	standard conditions	Figure 5 from Bu et al., 2021
pericardium edematous, abnormal	myh7l^xu093/xu093	chemical treatment by environment: cyclosporin A	Figure 3 from Bu et al., 2021
pericardium edematous, ameliorated	myh7l^xu093/xu093	chemical treatment by environment: sirolimus	Figure 3 from Bu et al., 2021
pericardium edematous, abnormal	myh7l^xu093/xu093	standard conditions	Figure 1 from Bu et al., 2021
whole organism myh7l expression decreased amount, abnormal	myh7l^xu093/+	standard conditions	Figure 1 from Bu et al., 2021
heart ab1-rps6 labeling increased amount, abnormal	myh7l^xu093/+	standard conditions	Figure 6 from Bu et al., 2021
myocardium disorganized, abnormal	myh7l^xu093/+	standard conditions	Figure 2 , Figure 6 from Bu et al., 2021
whole organism nppb expression increased amount, abnormal	myh7l^xu093/+	standard conditions	Figure 2 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/+	standard conditions	Figure 2 , Figure 6 from Bu et al., 2021
heart increased size, abnormal	myh7l^xu093/+	standard conditions	Figure 2 from Bu et al., 2021
heart Ab7-mtor labeling increased amount, abnormal	myh7l^xu093/+	standard conditions	Figure 6 from Bu et al., 2021
whole organism viability, abnormal	myh7l^xu093/+	standard conditions	Figure 2 from Bu et al., 2021
whole organism nppa expression increased amount, abnormal	myh7l^xu093/+	standard conditions	Figure 2 from Bu et al., 2021
swimming decreased rate, abnormal	myh7l^xu093/+	standard conditions	Figure 2 from Bu et al., 2021
cardiac ventricle surface feature shape, abnormal	myh7l^xu093/+	standard conditions	Figure 6 from Bu et al., 2021
whole organism viability, ameliorated	myh7l^xu093/xu093 + CRISPR2-mapk3	standard conditions	Figure 4 from Bu et al., 2021
heart increased size, ameliorated	myh7l^xu093/xu093 + CRISPR2-mapk3	standard conditions	Figure 4 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/xu093 + CRISPR2-mapk3	standard conditions	Figure 4 from Bu et al., 2021
atrium sarcomere ab-f59 labeling spatial pattern, ameliorated	myh7l^xu093/xu093 + CRISPR2-mapk3	standard conditions	Figure 4 from Bu et al., 2021
whole organism viability, ameliorated	myh7l^xu093/xu093 + CRISPR3-mtor	standard conditions	Figure 4 from Bu et al., 2021
heart increased size, ameliorated	myh7l^xu093/xu093 + CRISPR3-mtor	standard conditions	Figure 4 from Bu et al., 2021
atrium sarcomere ab-f59 labeling spatial pattern, ameliorated	myh7l^xu093/xu093 + CRISPR3-mtor	standard conditions	Figure 4 from Bu et al., 2021
heart contraction decreased process quality, abnormal	myh7l^xu093/xu093 + CRISPR3-mtor	standard conditions	Figure 4 from Bu et al., 2021
atrium sarcomere ab-f59 labeling spatial pattern, ameliorated	mapk3^xu092/xu092; myh7l^xu093/xu093	standard conditions	Figure 4 from Bu et al., 2021
cardiac muscle cell nucleus increased size, abnormal	mapk3^xu092/xu092; myh7l^xu093/xu093	standard conditions	Figure 5 from Bu et al., 2021
cardiac ventricle cardiac muscle cell shape, ameliorated	mapk3^xu092/xu092; myh7l^xu093/xu093	standard conditions	Figure 5 from Bu et al., 2021
myocardium disorganized, ameliorated	myh7l^xu093/+; mtor^xu015Gt/+	standard conditions	Figure 6 from Bu et al., 2021
heart Ab11-map1lc3 labeling increased amount, abnormal	myh7l^xu093/+; mtor^xu015Gt/+	standard conditions	Figure 6 from Bu et al., 2021
cardiac ventricle surface feature shape, ameliorated	myh7l^xu093/+; mtor^xu015Gt/+	standard conditions	Figure 6 from Bu et al., 2021
heart ab1-rps6 labeling amount, ameliorated	myh7l^xu093/+; mtor^xu015Gt/+	standard conditions	Figure 6 from Bu et al., 2021
heart contraction decreased process quality, ameliorated	myh7l^xu093/+; mtor^xu015Gt/+	standard conditions	Figure 6 from Bu et al., 2021
heart Ab7-mtor labeling increased amount, abnormal	myh7l^xu093/+; mtor^xu015Gt/+	standard conditions	Figure 6 from Bu et al., 2021
atrium sarcomere ab-f59 labeling spatial pattern, ameliorated	myh7l^xu093/xu093; mtor^{xu015Gt/xu015Gt}	standard conditions	Figure 4 from Bu et al., 2021
cardiac ventricle cardiac muscle cell amount, abnormal	myh7l^xu093/xu093; mtor^{xu015Gt/xu015Gt}	standard conditions	Figure 5 from Bu et al., 2021
cardiac muscle cell nucleus normal size, ameliorated	myh7l^xu093/xu093; mtor^{xu015Gt/xu015Gt}	standard conditions	Figure 5 from Bu et al., 2021
cardiac ventricle cardiac muscle cell shape, abnormal	myh7l^xu093/xu093; mtor^{xu015Gt/xu015Gt}	standard conditions	Figure 5 from Bu et al., 2021

Citations